$PBIO Extended Consumer Testing Strongly Validates
Post# of 1354
(Total Views: 180)
Posted On: 05/09/2023 9:46:47 AM
$PBIO Extended Consumer Testing Strongly Validates Market Transforming Speed and Dosing Efficiency of Pressure BioSciences UltraShear Processed Nano-THC Oral Spray
https://www.accesswire.com/753697/Extended-Co...Oral-Spray
Additional Focus Groups Corroborate UltraShear Nano-THC Produces Equal to Much Better THC Experiences, Even from Lower THC Dosing Levels; Also, Lightning-Fast Pain Relief from Topical Use.
SOUTH EASTON, MA / ACCESSWIRE / May 9, 2023 / Pressure BioSciences, Inc. (OTCQB
BIO) ("PBIO" or "Company"
today announced results from additional consumer focus group testing of a THC Nanoemulsion Oral Spray designed for rapid, direct absorption through the cheeks. The THC Nanoemulsion Oral Spray was prepared using PBI's revolutionary Ultra Shear Technology™ (UltraShear™) platform by PBI's California-based partner companies, including Crème De Canna (CdC), a CA-licensed manufacturer and long-established provider of innovative, high-quality cannabis products.
Additional consumer focus group testing more than doubled the original cohort of participants and has strongly affirmed multiple pivotal results on the UltraShear processed Nano-THC Oral Spray being powerfully differentiated from traditional THC dosing alternatives:
Speedy onset of first effects (average well under ten minutes - many reports in first few minutes) versus typical THC edibles requiring 30-60 minutes.
Much faster progression to maximum effects (average well under 40 minutes - many reports in 30 minutes or less) versus typical THC edibles requiring 60-120 minutes.
Eliminates health issues associated with smoking or vaping.
Enormous efficiency improvement in dose payload delivery allows equal to much better/greater THC experience from dosing down to a small fraction of user's normal dosing levels.
Stable, all plant formulation is sterile packaged with no added preservatives.
Multiple testers applied even a single spray to painful body areas and reported fast to instant transdermal pain relief.
Mr. John B. Hollister, PBIO's Director of Sales and Marketing, discussed highlights from the studies: "Most testing participants used lower doses of UltraShear Nano-THC than their usual dose level for THC products - and the vast majority of volunteers reported the same, more, or much more effect from the lower dosing of Nano-THC versus their normal dosing choices. Multiple normally heavy users of THC and many other participants reported onset of effects from the Nano-THC Oral Spray very quickly, even at significantly lower THC concentrations than usually consumed."
Mr. Hollister continued: "Following completion of the oral spray studies, we were also delighted by unplanned outcomes from multiple participants spraying the Nano-THC onto bodily pain locations (joint, arthritis, soreness, etc.) - and reporting very rapid, nearly instant relief from localized pain. All of these reported results are unsurprising to us, as scientific literature has long documented the greatly increased bioavailability of water-insoluble valuable constituents when dissolved into sufficiently small (under 100 nm) oil droplets. PBI's UltraShear platform accomplishes this with unmatched uniformity, tunable droplet size control, lower cost of production, better ease-of-use, and long-term stability."
Mr. Richard T. Schumacher, President and CEO of PBIO, concluded: "These extended study results have confirmed the potential for a market transformation in THC consumption with a new oral/transdermal dosing modality in between the existing smoke/vape and edible food/beverage bifurcation of this enormous market. We believe that the customer experience with UltraShear processed Nano-THC will be compelling to drive a tidal change in the market, with potential explosive adoption of UltraShear processed Nano-THC."
Mr. Schumacher continued: "We are experiencing similar reactions and developments as we work with early partners across multiple other markets in nutraceuticals, cosmeceuticals, food/beverage, and more. 2023 is poised to be a watershed transformational year for PBI, as we capitalize for roll-out of the UltraShear platform and converge upon our announced NASDAQ or NYSE uplisting goal."
https://www.accesswire.com/753697/Extended-Co...Oral-Spray
Additional Focus Groups Corroborate UltraShear Nano-THC Produces Equal to Much Better THC Experiences, Even from Lower THC Dosing Levels; Also, Lightning-Fast Pain Relief from Topical Use.
SOUTH EASTON, MA / ACCESSWIRE / May 9, 2023 / Pressure BioSciences, Inc. (OTCQB
BIO) ("PBIO" or "Company" today announced results from additional consumer focus group testing of a THC Nanoemulsion Oral Spray designed for rapid, direct absorption through the cheeks. The THC Nanoemulsion Oral Spray was prepared using PBI's revolutionary Ultra Shear Technology™ (UltraShear™) platform by PBI's California-based partner companies, including Crème De Canna (CdC), a CA-licensed manufacturer and long-established provider of innovative, high-quality cannabis products. Additional consumer focus group testing more than doubled the original cohort of participants and has strongly affirmed multiple pivotal results on the UltraShear processed Nano-THC Oral Spray being powerfully differentiated from traditional THC dosing alternatives:
Speedy onset of first effects (average well under ten minutes - many reports in first few minutes) versus typical THC edibles requiring 30-60 minutes.
Much faster progression to maximum effects (average well under 40 minutes - many reports in 30 minutes or less) versus typical THC edibles requiring 60-120 minutes.
Eliminates health issues associated with smoking or vaping.
Enormous efficiency improvement in dose payload delivery allows equal to much better/greater THC experience from dosing down to a small fraction of user's normal dosing levels.
Stable, all plant formulation is sterile packaged with no added preservatives.
Multiple testers applied even a single spray to painful body areas and reported fast to instant transdermal pain relief.
Mr. John B. Hollister, PBIO's Director of Sales and Marketing, discussed highlights from the studies: "Most testing participants used lower doses of UltraShear Nano-THC than their usual dose level for THC products - and the vast majority of volunteers reported the same, more, or much more effect from the lower dosing of Nano-THC versus their normal dosing choices. Multiple normally heavy users of THC and many other participants reported onset of effects from the Nano-THC Oral Spray very quickly, even at significantly lower THC concentrations than usually consumed."
Mr. Hollister continued: "Following completion of the oral spray studies, we were also delighted by unplanned outcomes from multiple participants spraying the Nano-THC onto bodily pain locations (joint, arthritis, soreness, etc.) - and reporting very rapid, nearly instant relief from localized pain. All of these reported results are unsurprising to us, as scientific literature has long documented the greatly increased bioavailability of water-insoluble valuable constituents when dissolved into sufficiently small (under 100 nm) oil droplets. PBI's UltraShear platform accomplishes this with unmatched uniformity, tunable droplet size control, lower cost of production, better ease-of-use, and long-term stability."
Mr. Richard T. Schumacher, President and CEO of PBIO, concluded: "These extended study results have confirmed the potential for a market transformation in THC consumption with a new oral/transdermal dosing modality in between the existing smoke/vape and edible food/beverage bifurcation of this enormous market. We believe that the customer experience with UltraShear processed Nano-THC will be compelling to drive a tidal change in the market, with potential explosive adoption of UltraShear processed Nano-THC."
Mr. Schumacher continued: "We are experiencing similar reactions and developments as we work with early partners across multiple other markets in nutraceuticals, cosmeceuticals, food/beverage, and more. 2023 is poised to be a watershed transformational year for PBI, as we capitalize for roll-out of the UltraShear platform and converge upon our announced NASDAQ or NYSE uplisting goal."
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼